FDA okays first cardiac myosin inhibitor

FDA okays first cardiac myosin inhibitor

Approval was based on the phase 3 Explorer-HCM trial in 251 patients with New York Heart Association class II–III obstructive HCM, all of whom had left ventricular ejection fraction (LVEF)>55% or higher. Because the drug, an allosteric small moleule, depresses cardiac contractility by inhibiting cardiac-specific myosin, adverse reactions were a concern. But none of the subjects experienced left ventricular ejection fraction ≤30% nor congestive heart failure, syncope or sudden cardiac death in the Camzyos group. Two patients who transiently experienced LVEF ≤50% interrupted treatment and resumed it on a lower dose.

This is a preview of subscription content

Access options

Subscribe to Journal

Get full journal access for 1 year

99,00 €

only 8,25 € per issue

Tax calculation will be finalised during checkout.

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Cite this article

FDA okays first cardiac myosin inhibitor.
Nat Biotechnol 40, 809 (2022). https://doi.org/10.1038/s41587-022-01374-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01374-3

Read More

Author: admin